Efficacy of Corticosteroids and External Beam Radiation in the Management of Moderate to Severe Thyroid Eye Disease

Thyroid Eye Disease (TED, Graves ophthalmopathy, thyroid ophthalmopathy) is the most common cause of orbital inflammation and proptosis in adults. There is no agreement on its management although corticosteroids and external beam orbital radiation (XRT) have traditionally been believed to provide benefit in active inflammation. Our review of the published literature in English disclosed an overall corticosteroid-mediated treatment response of 66.9% in a total of 834 treated patients who had moderate or severe TED. Intravenous corticosteroids used in repeated weekly pulses were more effective (overall favorable response = 74.6%, n = 177) and had fewer side effects than daily oral corticosteroids (overall favorable response = 55.5%, n = 265). A combination of corticosteroid and radiation therapy seemed to be more effective than corticosteroids alone. Our conclusions are tempered by a notable lack of standardization within and between study designs, treatment protocols, and outcome measures. Accordingly, the North American Neuro-Ophthalmology Society (NANOS), American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) and the Orbital Society, in conjunction with Neuro-Ophthalmology Research and Development Consortium (NORDIC), will investigate the design and funding of a multi-center controlled trial.

[1]  M. Erdoğan,et al.  New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graves' ophthalmopathy , 2006, Endocrine.

[2]  G. Hommel,et al.  Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. , 2005, The Journal of clinical endocrinology and metabolism.

[3]  M. Devoto,et al.  Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone , 2004, British Journal of Ophthalmology.

[4]  R. Hoermann,et al.  Impact of smoking on the response to treatment of thyroid associated ophthalmopathy , 2003, The British journal of ophthalmology.

[5]  M. Nardi,et al.  Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. , 2003, European journal of endocrinology.

[6]  J. Earle,et al.  The aftermath of orbital radiotherapy for graves' ophthalmopathy. , 2002, Ophthalmology.

[7]  P. Rubin,et al.  The pathophysiology of thyroid-associated ophthalmopathy. , 2002, Ophthalmology clinics of North America.

[8]  Terry J. Smith,et al.  Insights into the pathogenesis of thyroid-associated orbitopathy: evolving rationale for therapy. , 2002, Archives of ophthalmology.

[9]  Jeffrey Colegrove.  Practical Diagnosis and Management of Orbital Disease. , 2002 .

[10]  L. Clauser,et al.  Rationale of Treatment in Graves Ophthalmopathy , 2001, Plastic and reconstructive surgery.

[11]  P. Diem,et al.  Graves' ophthalmopathy: natural history and treatment outcomes. , 2001, Swiss medical weekly.

[12]  J. Earle,et al.  A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. , 2001, Ophthalmology.

[13]  P. Perros,et al.  Controversies in the clinical evaluation of active thyroid‐associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment , 2001, Clinical endocrinology.

[14]  M. Nardi,et al.  Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. , 2001, The Journal of clinical endocrinology and metabolism.

[15]  P. Macchia,et al.  High-dose intravenous corticosteroid therapy for Graves’ ophthalmopathy , 2001, Journal of endocrinological investigation.

[16]  W. Hauff,et al.  Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. , 2000, Thyroid : official journal of the American Thyroid Association.

[17]  F. Epstein,et al.  [Pathogenesis of Graves' ophthalmopathy]. , 1993, Zeitschrift fur arztliche Fortbildung und Qualitatssicherung.

[18]  W. Wiersinga,et al.  Current management of thyroid‐associated ophthalmopathy in Europe. Results of an international survey , 1998, Clinical endocrinology.

[19]  C. Gorman,et al.  The measurement of change in Graves' ophthalmopathy. , 1998, Thyroid : official journal of the American Thyroid Association.

[20]  G. Vaillant,et al.  Intravenous Methylprednisolone Pulse Therapy in the Treatment of Graves' Ophthalmopathy , 1998, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[21]  M. Nardi,et al.  Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. , 1998, The New England journal of medicine.

[22]  T. C. Chang,et al.  Relationships of orbital computed tomographic findings and activity scores to the prognosis of corticosteroid therapy in patients with Graves' ophthalmopathy , 2009 .

[23]  A. Antonelli,et al.  Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy. , 1997, Thyroid : official journal of the American Thyroid Association.

[24]  R. Müller,et al.  Results and prognostic factors in retrobulbar radiotherapy combined with systemic corticosteroids for endocrine orbitopathy (Graves' disease). , 1997, Frontiers of radiation therapy and oncology.

[25]  R. Harrad,et al.  Combined radiotherapy and medical immunosuppression in the management of thyroid eye disease , 1997, Eye.

[26]  K. Nakao,et al.  High-dose intravenous steroid pulse therapy in thyroid-associated ophthalmopathy. , 1996, Endocrine journal.

[27]  K. Hayakawa,et al.  Therapy of Graves' ophthalmopathy with intravenous high-dose steroid followed by orbital irradiation. , 1994, Thyroid : official journal of the American Thyroid Association.

[28]  L. Blank,et al.  Randomised double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy , 1993, The Lancet.

[29]  D. Glinoer,et al.  Use of eye muscle antibody measurements to monitor response to plasmapheresis in patients with thyroid-associated ophthalmopathy , 1993, Journal of endocrinological investigation.

[30]  K. Kojima,et al.  Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy. , 1992, Thyroid : official journal of the American Thyroid Association.

[31]  A. Antonelli,et al.  High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy. , 1992, Acta endocrinologica.

[32]  A. Pinchera,et al.  Glucocorticoid therapy of Graves' ophthalmopathy. , 2009, Experimental and clinical endocrinology.

[33]  S. Trokel,et al.  Treatment of acute Graves orbitopathy. , 1991, Ophthalmology.

[34]  M. Prummel,et al.  Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. , 1989, The New England journal of medicine.

[35]  L Koornneef,et al.  Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. , 1989, The British journal of ophthalmology.

[36]  P. Dandona,et al.  Methylprednisolone and Graves' ophthalmopathy. , 1989, BMJ.

[37]  P. Kendall‐Taylor,et al.  Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy. , 1988, BMJ.

[38]  C. Marcocci,et al.  ORBITAL COBALT IRRADIATION COMBINED WITH RETROBULBAR OR SYSTEMIC CORTICOSTEROIDS FOR GRAVES' OPHTHALMOPATHY: A COMPARATIVE STUDY , 1987, Clinical endocrinology.

[39]  S. Dresner,et al.  Dysthyroid orbitopathy , 1985, Neurology.

[40]  C. Marcocci,et al.  Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. , 1983, The Journal of clinical endocrinology and metabolism.

[41]  T. Takai,et al.  Treatment of Graves' ophthalmopathy by steroid therapy, orbital radiation therapy, plasmapheresis and thyroxine replacement. , 1982, Endocrinologia japonica.

[42]  R. Sergott,et al.  Graves' ophthalmopathy. A clinical and immunologic review. , 1981, Survey of ophthalmology.

[43]  J. Trobe,et al.  Dysthyroid Optic Neuropathy: Clinical Profile and Rationale for Management , 1978 .

[44]  G. Burrow,et al.  Immunosuppressive therapy for the eye changes of Graves' disease. , 1970, The Journal of clinical endocrinology and metabolism.

[45]  S C Werner,et al.  Classification of the eye changes of Graves' disease. , 1969, American journal of ophthalmology.

[46]  M. Garber.  Methylprednisolone in the treatment of exophthalmos. , 1966, Lancet.